ABSTRACT
A 67-year-old woman was found to have multiple liver abscess and pneumonia. Liver abscess was improved after percutaneous transhepatic abscess drainage(PTAD). A diagnosis of rectal cancer was made by colonoscopy and the patient underwent colostomy for rectal cancer on February 2018. Laparoscopic low anterior resection was performed on July 2019 after mFOLFOX plus bevacizumab(BEV)14 courses. Lower leaf partial lung resection was performed on September 2019 and upper leaf partial resection was performed on September 2020 for lung metastasis. The patient is currently alive without relapse after 21 months. Liver abscess was caused by portal vein infection of rectal cancer. Effective chemotherapy with surgery was successful.
Subject(s)
Liver Abscess , Liver Neoplasms , Rectal Neoplasms , Female , Humans , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Rectal Neoplasms/complications , Rectal Neoplasms/drug therapy , Rectal Neoplasms/surgery , Liver Abscess/surgery , Bevacizumab , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Liver Neoplasms/secondaryABSTRACT
A 56-year-old man was revealed to be HCC with portal vein tumor thrombus. Curative operation was impossible because we recognized many daughter lesions in the liver. Tumor marker was very high. DSM-TACE was conducted as the first line therapy. There was no remarkable side effect. After two-course, the size of HCC was decreased in CT and tumor marker was normalized. Generally speaking, a prognosis of HCC with portal vein tumor thrombus is poor. Hence, DSM-TACE is one of the effective therapies for HCC with portal vein tumor thrombus.
Subject(s)
Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic/methods , Liver Neoplasms/therapy , Venous Thrombosis/etiology , Humans , Male , Microspheres , Middle Aged , Neoplastic Cells, Circulating , StarchABSTRACT
A 68-year-old man was found to have a gallbladder cancer. Curative operation was impossible because the gallbladder cancer invaded around the gallbladder in CT on 15th of April, 2008. S-1 monotherapy (120 mg/day) was started. S-1 was given orally twice daily for 4 weeks followed by 2 weeks without a treatment. There was no remarkable side effect. The gallbladder cancer was smaller in CT on 25th of September, 2008, and we confirmed a partial response (PR) in CT on 13th of February, 2009. In a pilot phase II study of S-1 for biliary tract cancer, the overall objective response rate was 35.0%. There was no severe side effect. S-1 is one of the effective drugs for biliary tract cancer.
